Skip to Content

Olodaterol / Tiotropium Dosage

Medically reviewed on August 28, 2017.

Applies to the following strengths: 2.5 mcg-2.5 mcg/inh

Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance

-2 inhalations orally once a day, at the same time
Maximum dose: 2 inhalations every 24 hours

Use: Long-term treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema

Renal Dose Adjustments

Mild renal dysfunction: No adjustment recommended.
Moderate to Severe renal dysfunction (CrCl less than 60 mL/min): Use with caution; monitor closely for anticholinergic side effects

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction: A study was not performed.


Asthma-Related Death:
- Long-acting beta2-adrenergic agonists (LABA) such as olodaterol, one of the active ingredients in this drug, increase the risk of asthma-related death.
-A placebo-controlled study with another long-acting beta2-adrenergic agonist (salmeterol) showed an increase in asthma-related deaths in patients receiving salmeterol.
-This finding with salmeterol is considered a class effect of all LABA, including olodaterol, one of the active ingredients in this drug.
-The safety and efficacy of this drug in patients with asthma have not been established. This drug is not indicated for the treatment of asthma.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-Administer this drug at the same time of the day.
-The recommended daily dose should not be exceeded.
-This drug is for oral inhalation only.
-To ensure proper use of the inhalation device, see Instructions for its use.

-This drug is not indicated to treat acute deteriorations of COPD and asthma.
-The safety and effectiveness of this drug in asthma patients have not been established.

Patient advice:
-Patients should read the medication guide and instructions for the use of this drug.
-Notify the physician immediately if experiencing any of the following: Worsening of symptoms; decreasing effectiveness of inhaled, short-acting beta2-agonists; need for more inhalations than usual of the inhaled, short-acting beta2-agonists; significant decrease in lung function as outlined by the physician.
-Therapy with this drug should not be stopped without physician/provider guidance since symptoms may recur after discontinuation.
-Discontinue previous regular use of short acting beta2-agonist and use them only for the symptomatic relief of acute symptoms.
-Consult a provider immediately if symptoms of eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema develop. The use of miotic eye drops alone is not considered to be effective treatment.
-Caution must be taken not to allow the aerosol cloud to enter into the eyes as this may cause blurring of vision and pupil dilation.
-This drug can cause dizziness and blurred vision, caution is recommended when driving or operating or machinery.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.